This review explores the #PI3K signaling pathway and its role in reshaping #CellSignaling, #MetabolicProcesses, and the #TumorMicroenvironment, highlighting emerging #therapeutic strategies for #PIK3CA-mutant #Tumors. #medsky
#OpenAccess: www.sciencedirect.com/science/arti...
#OpenAccess: www.sciencedirect.com/science/arti...
November 8, 2025 at 12:37 PM
This review explores the #PI3K signaling pathway and its role in reshaping #CellSignaling, #MetabolicProcesses, and the #TumorMicroenvironment, highlighting emerging #therapeutic strategies for #PIK3CA-mutant #Tumors. #medsky
#OpenAccess: www.sciencedirect.com/science/arti...
#OpenAccess: www.sciencedirect.com/science/arti...
Months later, after chemo, surgery removes the tumor.
Another sequence done.
KRAS mutation gone. New PIK3CA mutation appears.
Same patient. Different tumor. This isn't magic—it's evolution.
Another sequence done.
KRAS mutation gone. New PIK3CA mutation appears.
Same patient. Different tumor. This isn't magic—it's evolution.
November 7, 2025 at 2:15 PM
Months later, after chemo, surgery removes the tumor.
Another sequence done.
KRAS mutation gone. New PIK3CA mutation appears.
Same patient. Different tumor. This isn't magic—it's evolution.
Another sequence done.
KRAS mutation gone. New PIK3CA mutation appears.
Same patient. Different tumor. This isn't magic—it's evolution.
In the INAVO120 trial, inavolisib+palbociclib-fulvestrant improved PFS in PIK3CA-mutated, HR+HER2- advanced breast cancer vs placebo+palbociclib-fulvestrant. PMID:40454641, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2501796 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2501796
No description available
doi.org
November 3, 2025 at 1:10 AM
Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease - Kidney International www.kidney-international.org/article/S008...
Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease
PI3Kα is a ubiquitous lipid kinase that transduces extracellular growth, proliferation
and metabolism signals. Genes involved in the PI3Kα signaling pathway are frequently
mutated in cancer. Apart fro...
www.kidney-international.org
November 2, 2025 at 5:42 PM
Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease - Kidney International www.kidney-international.org/article/S008...
Review: Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease
#openaccess
#nephsky
#openaccess
#nephsky
Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease
PI3Kα is a ubiquitous lipid kinase that transduces extracellular growth, proliferation and metabolism signals. Genes involved in the PI3Kα signaling pathway are frequently mutated in cancer. Apart…
www.kidney-international.org
November 1, 2025 at 6:01 PM
Review: Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease
#openaccess
#nephsky
#openaccess
#nephsky
Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.
💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk
#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk
#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer - VJOncology
Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, comments on discusses final survival results from the EMERALD study (NCT03264547)...
buff.ly
November 1, 2025 at 9:01 AM
Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.
💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk
#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk
#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
PI3Kα inhibitor and degrader inavolisib can co-opt FGFR2 to enhance responses in patients with PIK3CA-mutated solid tumors and in preclinical models aacrjournals.org/clincancerre... #hvhebron #onco [Text complet]
PI3Kα inhibitor and degrader inavolisib can co-opt FGFR2 to enhance responses in patients with PIK3CA-mutated solid tumors and in preclinical models
Abstract. Background: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor-positive (HR+) breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degr...
aacrjournals.org
October 30, 2025 at 3:22 PM
PI3Kα inhibitor and degrader inavolisib can co-opt FGFR2 to enhance responses in patients with PIK3CA-mutated solid tumors and in preclinical models aacrjournals.org/clincancerre... #hvhebron #onco [Text complet]
Today is the final webinar in our series on molecular testing for HR+/HER- breast cancer. We'll show how specific genomic alterations (e.g., PIK3CA & ESR1 variants) can guide personalized treatment strategies and improve outcomes.
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
October 30, 2025 at 1:00 PM
Today is the final webinar in our series on molecular testing for HR+/HER- breast cancer. We'll show how specific genomic alterations (e.g., PIK3CA & ESR1 variants) can guide personalized treatment strategies and improve outcomes.
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
Aspirin may reduce cancer recurrence in patients with *PIK3CA* mutations and lower certain cancer risks, but overall evidence for cancer prevention or survival is mixed and more trials are needed. View in Timelines
October 29, 2025 at 2:01 PM
Aspirin may reduce cancer recurrence in patients with *PIK3CA* mutations and lower certain cancer risks, but overall evidence for cancer prevention or survival is mixed and more trials are needed. View in Timelines
TODAY is the 2nd webinar in our free series on concepts in molecular testing for HR+/HER- breast cancer. We’ll focus on evaluating assay performance in molecular laboratories for ESR1, PIK3CA, AKT1 & PTEN mutations in breast cancer
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
October 27, 2025 at 1:00 PM
TODAY is the 2nd webinar in our free series on concepts in molecular testing for HR+/HER- breast cancer. We’ll focus on evaluating assay performance in molecular laboratories for ESR1, PIK3CA, AKT1 & PTEN mutations in breast cancer
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...
Learn more about the study www.gbg.de/en/trials/ge...
GeparPiPPa
Phase II trial comparing neoadjuvant endocrine therapy in combination with the PI3K-Inhibitor Inavolisib
www.gbg.de
October 24, 2025 at 3:38 PM
#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...
Learn more about the study www.gbg.de/en/trials/ge...
Oct. 30: the final webinar in our FREE series on concepts in molecular testing for HR+/HER- breast cancer, showing how specific genomic alterations (e.g., PIK3CA & ESR1 variants)can guide treatment strategies & improve outcomes.
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
October 24, 2025 at 1:01 PM
Oct. 30: the final webinar in our FREE series on concepts in molecular testing for HR+/HER- breast cancer, showing how specific genomic alterations (e.g., PIK3CA & ESR1 variants)can guide treatment strategies & improve outcomes.
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
#ArticleinPress: Comparative Performance of a Targeted Next-Generation Sequencing Assay Against Multiplexed Digital PCR Assays in Detecting ERBB2, ESR1, and PIK3CA Mutations in Plasma Circulating Cell-Free DNA from Liquid Biopsies.
Full text: https://loom.ly/YZGyEqc
Full text: https://loom.ly/YZGyEqc
October 23, 2025 at 7:38 PM
#ArticleinPress: Comparative Performance of a Targeted Next-Generation Sequencing Assay Against Multiplexed Digital PCR Assays in Detecting ERBB2, ESR1, and PIK3CA Mutations in Plasma Circulating Cell-Free DNA from Liquid Biopsies.
Full text: https://loom.ly/YZGyEqc
Full text: https://loom.ly/YZGyEqc
Oct. 27 is the second webinar in our free series on concepts in molecular testing for HR+/HER- breast cancer, focused on evaluating assay performance in molecular laboratories for ESR1, PIK3CA, AKT1& PTEN mutations in breast cancer
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
October 23, 2025 at 1:01 PM
Oct. 27 is the second webinar in our free series on concepts in molecular testing for HR+/HER- breast cancer, focused on evaluating assay performance in molecular laboratories for ESR1, PIK3CA, AKT1& PTEN mutations in breast cancer
https://educate.amp.org/local/catalog/view/product.php?productid=577
https://educate.amp.org/local/catalog/view/product.php?productid=577
Thrilled to welcome our first plenary speaker Mariona Graupera @grauperalab.bsky.social - beautiful work on endothelial cell plasticity in obesity and PIK3CA-driven vascular malformations
October 23, 2025 at 12:38 AM
Thrilled to welcome our first plenary speaker Mariona Graupera @grauperalab.bsky.social - beautiful work on endothelial cell plasticity in obesity and PIK3CA-driven vascular malformations
#PostTest Q2️⃣ #TumorBoardTuesday
🧐A 75yo♀️w/ ER+/HER2- PIK3CA+ mBC starts 2L Tx w/alpelisib + fulvestrant. Baseline A1C = 6.1 & BMI = 33. What steps can limit risk for severe hyperglycemia❓
1) Labs QW x 2, then Qmonth
2) Baseline A1C, then Q3 months
3) Consider metformin premed
4) All of the above
🧐A 75yo♀️w/ ER+/HER2- PIK3CA+ mBC starts 2L Tx w/alpelisib + fulvestrant. Baseline A1C = 6.1 & BMI = 33. What steps can limit risk for severe hyperglycemia❓
1) Labs QW x 2, then Qmonth
2) Baseline A1C, then Q3 months
3) Consider metformin premed
4) All of the above
Integrity CE
Learn more about the
integrityce.com
October 22, 2025 at 1:25 AM
#PostTest Q2️⃣ #TumorBoardTuesday
🧐A 75yo♀️w/ ER+/HER2- PIK3CA+ mBC starts 2L Tx w/alpelisib + fulvestrant. Baseline A1C = 6.1 & BMI = 33. What steps can limit risk for severe hyperglycemia❓
1) Labs QW x 2, then Qmonth
2) Baseline A1C, then Q3 months
3) Consider metformin premed
4) All of the above
🧐A 75yo♀️w/ ER+/HER2- PIK3CA+ mBC starts 2L Tx w/alpelisib + fulvestrant. Baseline A1C = 6.1 & BMI = 33. What steps can limit risk for severe hyperglycemia❓
1) Labs QW x 2, then Qmonth
2) Baseline A1C, then Q3 months
3) Consider metformin premed
4) All of the above
🧐 A 75yo ♀️w/ ER+/HER2- PIK3CA+ mBC is starting 2L therapy with alpelisib + fulvestrant. Baseline A1C is 6.1 and BMI is 33. What steps can limit risk for severe hyperglycemia❓
October 22, 2025 at 1:06 AM
🧐 A 75yo ♀️w/ ER+/HER2- PIK3CA+ mBC is starting 2L therapy with alpelisib + fulvestrant. Baseline A1C is 6.1 and BMI is 33. What steps can limit risk for severe hyperglycemia❓
11/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 6🏫
⬆️ Elacestrant benefited all subgroups including: 🦴only, 🫁 visceral mets, > 3 mets
⬆️ Elacestrant benefited all🧬subgroups: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Most common AE: N/V
👩🏻🏫Mini Tweetorial 6🏫
⬆️ Elacestrant benefited all subgroups including: 🦴only, 🫁 visceral mets, > 3 mets
⬆️ Elacestrant benefited all🧬subgroups: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Most common AE: N/V
ASCO Publications
ascopubs.org
October 22, 2025 at 12:45 AM
11/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 6🏫
⬆️ Elacestrant benefited all subgroups including: 🦴only, 🫁 visceral mets, > 3 mets
⬆️ Elacestrant benefited all🧬subgroups: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Most common AE: N/V
👩🏻🏫Mini Tweetorial 6🏫
⬆️ Elacestrant benefited all subgroups including: 🦴only, 🫁 visceral mets, > 3 mets
⬆️ Elacestrant benefited all🧬subgroups: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Most common AE: N/V
8/18 #TumorBoardTuesday
Back to our case🔎
👉 Everolimus + fulvestrant is not favored given the more targeted approach with Capivasterib for the PIK3CA mutation
✅ Tolerated therapy well with mild rash at start of treatment that resolved with antihistamines
Back to our case🔎
👉 Everolimus + fulvestrant is not favored given the more targeted approach with Capivasterib for the PIK3CA mutation
✅ Tolerated therapy well with mild rash at start of treatment that resolved with antihistamines
October 22, 2025 at 12:38 AM
8/18 #TumorBoardTuesday
Back to our case🔎
👉 Everolimus + fulvestrant is not favored given the more targeted approach with Capivasterib for the PIK3CA mutation
✅ Tolerated therapy well with mild rash at start of treatment that resolved with antihistamines
Back to our case🔎
👉 Everolimus + fulvestrant is not favored given the more targeted approach with Capivasterib for the PIK3CA mutation
✅ Tolerated therapy well with mild rash at start of treatment that resolved with antihistamines
8/18 #TumorBoardTuesday
Back to our case🔎
👩🦳 Patient received Capivasertib + Fulvestrant due to PIK3CA mutation.
👉 Not yet considered endocrine resistant so would not move onto capecitabine, sacituzumab
👉 Tumor is HER2 negative so no role for trastuzumab deruxtecan
Back to our case🔎
👩🦳 Patient received Capivasertib + Fulvestrant due to PIK3CA mutation.
👉 Not yet considered endocrine resistant so would not move onto capecitabine, sacituzumab
👉 Tumor is HER2 negative so no role for trastuzumab deruxtecan
October 22, 2025 at 12:38 AM
8/18 #TumorBoardTuesday
Back to our case🔎
👩🦳 Patient received Capivasertib + Fulvestrant due to PIK3CA mutation.
👉 Not yet considered endocrine resistant so would not move onto capecitabine, sacituzumab
👉 Tumor is HER2 negative so no role for trastuzumab deruxtecan
Back to our case🔎
👩🦳 Patient received Capivasertib + Fulvestrant due to PIK3CA mutation.
👉 Not yet considered endocrine resistant so would not move onto capecitabine, sacituzumab
👉 Tumor is HER2 negative so no role for trastuzumab deruxtecan
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1 - PubMed
NCT02437318.
pubmed.ncbi.nlm.nih.gov
October 22, 2025 at 12:38 AM
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
📎 pubmed.ncbi.nlm.nih.gov/33246021/
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
✌️Alpelisib & Capivasertib are approved in 2nd line mER+ BC combined with fulvestrant
🔎 NGS results, Baseline A1C
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
✌️Alpelisib & Capivasertib are approved in 2nd line mER+ BC combined with fulvestrant
🔎 NGS results, Baseline A1C
October 22, 2025 at 12:38 AM
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
✌️Alpelisib & Capivasertib are approved in 2nd line mER+ BC combined with fulvestrant
🔎 NGS results, Baseline A1C
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
✌️Alpelisib & Capivasertib are approved in 2nd line mER+ BC combined with fulvestrant
🔎 NGS results, Baseline A1C
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
☝️Inavolisib+Fulvestrant+Palbo is approved for 1st line mER+ BC after recurrence on/after adjuvant ET therapy
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
☝️Inavolisib+Fulvestrant+Palbo is approved for 1st line mER+ BC after recurrence on/after adjuvant ET therapy
October 22, 2025 at 12:38 AM
7/18 #TumorBoardTuesday
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
☝️Inavolisib+Fulvestrant+Palbo is approved for 1st line mER+ BC after recurrence on/after adjuvant ET therapy
👩🏻🏫Mini Tweetorial 4🏫
💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib
🤔 When and how do you PIK one of the PIK3CA of the 3 available?
☝️Inavolisib+Fulvestrant+Palbo is approved for 1st line mER+ BC after recurrence on/after adjuvant ET therapy
EMERALD Con't
⬆️ PFS: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Common AE nausea, vomiting
📎Bidard et al. Elacestrant vs standard endocrine therapy for estrogen receptor-positive human epidermal growth factor receptor 2-neg advanced breast cancer. JCO. 2022.
Link: ascopubs.org/doi/10.1200/...
⬆️ PFS: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Common AE nausea, vomiting
📎Bidard et al. Elacestrant vs standard endocrine therapy for estrogen receptor-positive human epidermal growth factor receptor 2-neg advanced breast cancer. JCO. 2022.
Link: ascopubs.org/doi/10.1200/...
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Resu...
PURPOSEPatients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor
receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. Elacestrant
is a novel, oral select...
ascopubs.org
October 22, 2025 at 12:36 AM
EMERALD Con't
⬆️ PFS: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Common AE nausea, vomiting
📎Bidard et al. Elacestrant vs standard endocrine therapy for estrogen receptor-positive human epidermal growth factor receptor 2-neg advanced breast cancer. JCO. 2022.
Link: ascopubs.org/doi/10.1200/...
⬆️ PFS: ✔️ESR1+PIK3CA, ✔️ESR1+TP53, ✔️ESR1+HER2-low
🤢 Common AE nausea, vomiting
📎Bidard et al. Elacestrant vs standard endocrine therapy for estrogen receptor-positive human epidermal growth factor receptor 2-neg advanced breast cancer. JCO. 2022.
Link: ascopubs.org/doi/10.1200/...
#tumorboardtuesday
Any subtle differences in outcomes based on the specific mutation identified
AKT vs. PTEN vs. PIK3CA❓
Any subtle differences in outcomes based on the specific mutation identified
AKT vs. PTEN vs. PIK3CA❓
October 22, 2025 at 12:29 AM
#tumorboardtuesday
Any subtle differences in outcomes based on the specific mutation identified
AKT vs. PTEN vs. PIK3CA❓
Any subtle differences in outcomes based on the specific mutation identified
AKT vs. PTEN vs. PIK3CA❓